Some apolipoproteins are associated with type 2 diabetes

The proportion of apolipoprotein (apo) CIII and apoCIII to apoA1 is associated with type 2 diabetes (T2D), according to a study published in the December 28 issue of Diabetes Care, which also has some other studies on recombinant human proteins.

Dr. Adela Brahimaj and colleagues from the Erasmus University Medical Center in Rotterdam, the Netherlands, and used data from 971 individuals from the population-based Rotterdam study to examine the role of apolipoprotein in the risk of type 2 diabetes. They examined the association of high-density lipoprotein cholesterol (HDL-C), apoA1, apoCIII, apoD and apoE, and the ratio of apolipoprotein to apoA1 and T2D risk.

The researchers found that at a median follow-up of 13.5 years, 110 people developed diabetes. Apolipoprotein E, apoA / apoA1 ratio, apoE to apoA1 ratio and apolipoprotein score remained significant after adjusting for age, sex, body mass index, diabetes maternal history, hypertension, alcohol use, smoking, diabetes mellitus. The prevalence of cardiovascular disease was associated with a serum lipid-lowering agent (odds ratios of 0.74, 1.65, 1.36, 1.72, 1.88 and 1.6 for each standard deviation of natural logarithmic conversion). After adjustment for triglycerides in the final model, only apoCIII and apoCIII-to-apoA1 ratios remained significant (hazard ratios, 1.42 and 1.56, respectively).

"Serum apoCIII levels and apoCIII-to-apoA1 ratios are associated with incident type 2 diabetes," the authors write. They are independent of known risk factors and are stronger than HDL-C levels. Flarbio provides high-quality recombinant proteins like recombinant Itgb2 at competitive prices.